Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Operating Leases (2021 - 2026)

Design Therapeutics' Operating Leases history spans 1 years, with the latest figure at $3.1 million for Q4 2021.

  • On a quarterly basis, Operating Leases changed N/A to $3.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $3.1 million, a N/A change, with the full-year FY2021 number at $3.1 million, changed N/A from a year prior.
  • Operating Leases hit $3.1 million in Q4 2021 for Design Therapeutics, down from $3.3 million in the prior quarter.
  • Over the last five years, Operating Leases for DSGN hit a ceiling of $3.3 million in Q3 2021 and a floor of $3.1 million in Q4 2021.